GORE PROPATEN® Vascular Graft

GORE PROPATEN® Vascular Graft



Addressing the problem of thrombus formation on the luminal surface of a vascular graft is a challenge faced by all vascular surgeons.

The GORE PROPATEN® Vascular Graft is specifically designed for those vascular procedures in which the risk of acute graft thrombotic failure is of clinical concern.
Anything better below-knee would be a vein
Overall weighted average* primary patency based on GORE PROPATEN® Vascular Graft literature in below knee bypasses

*See references (PDF)

The GORE PROPATEN® Vascular Graft harnesses the anticoagulant properties of heparin directly at the luminal surface of the graft. The proprietary end-point attachment mechanism serves to anchor heparin molecules to the luminal surface while still maintaining heparin’s intrinsic bioactive properties. The result: a thromboresistant BioActive graft surface that retains its bioactive properties over time.

The GORE PROPATEN® Vascular Graft has demonstrated improved thromboresistance and patency compared to standard ePTFE grafts in pre-clinical in vivo tests. The thromboresistant surface technology employed on the GORE PROPATEN® Vascular Graft is designed to maintain bioactivity over an extended time period, thus increasing the potential for sustained performance improvement and increased patency*.

*Long-term data are not available regarding improved patency compared to marketed grafts.

GORE HELEX Septal Occluder

GORE HELEX Septal Occluder

Open heart surgery is no longer the only available option to correct atrial septal defects in young children and in patients with complicating health factors. Today's health care providers are seeking safe & effective non-surgical options to close inter-atrial defects.

The GORE HELEX Septal Occluder is a permanently implanted prosthesis and catheter delivery system indicated for the transcatheter closure of ostium secundum atrial septal defects (ASDs). The pre-assembled delivery system allows easy deployment of the device via standard femoral venous access.

The Occluder, which is composed of ePTFE patch material supported by a single nitinol wire frame, bridges and eventually occludes the septal defect to stop the shunting of blood between the atria. Over the course of several weeks to months, cells begin to infiltrate and grow over the ePTFE membrane, ensuring successful closure of the defect.